All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Brentuximab vedotin receives positive CHMP opinion in combination with CHP as treatment for adult patients with previously untreated sALCL
By Alia Mohamed
On March 31, 2020, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization for the anti-CD30 antibody–drug conjugate, brentuximab vedotin. The CHMP recommended its approval in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).1
The CHMP decision was based on positive data from the phase III ECHELON-2 trial (NCT01777152). The trial demonstrated favorable clinical activity of brentuximab vedotin plus CHP vs cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as first-line treatment in patients with CD30+ peripheral T-cell lymphoma (PTCL), which included the sALCL subtype. Treatment with brentuximab vedotin plus CHP improved progression-free survival by 29% compared to CHOP administration, with a comparable safety profile. 1
Read the Lymphoma Hub’s coverage of the ECHELON-2 trial here, and watch Ranjana Advani discuss it below.
ECHELON-2 trial: response by CD30 expression
- PipelineReview. Takeda receives positive CHMP opinion for ADCETRIS in combination w/ CHP for adult patients with previously untreated sALCL. https://pipelinereview.com/index.php/2020040174172/Antibodies/Takeda-Receives-Positive-CHMP-Opinion-for-ADCETRIS-in-Combination-w/-CHP-for-Adult-Patients-with-Previously-Untreated-sALCL.html. Published Apr 01, 2020. Accessed Apr 02, 2020.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youNewsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox